ArticleBioengineering & translational medicine2026
Enabling in vivo imaging in low-resource settings: Computed tomography imaging of gold-loaded polymersomes for the detection of glioblastoma.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early career innovators shaping the future of bioengineering and translational medicine.Bioengineering & translational medicine · 2026Article
- Enabling in vivo imaging in low-resource settings: Computed tomography imaging of gold-loaded polymersomes for the detection of glioblastoma.Bioengineering & translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Glioblastoma (GBM) is one of the most aggressive and rapidly progressing brain tumors, characterized by a low survival rate, in part due to insufficient diagnostic tools. Computed tomography (CT), although widely available, is limited in use for GBM diagnosis by the suboptimal performance of current clinically approved contrast agents. This study focuses on the development of gold nanoparticle (AuNP)-loaded polymersomes (AuPs) to improve the detection of GBM. We synthesized polyethylene glycol-b-polylactic acid (PEG-b-PLA) polymersomes with high AuNP loading. Increasing the concentrations of AuNPs in polymersomes resulted in enhanced contrast using clinical CT. Furthermore, AuPs bound to cell-penetrating peptide TAT were cytocompatible with U87-MG GBM cells at concentrations up to 100 mg/mL. Uptake studies using both fluorescence microscopy and flow cytometry confirmed the internalization of AuPs into GBM cells, with a direct correlation between AuP concentration and uptake efficiency. MicroCT imaging also confirmed a similar trend; >300% enhanced contrast compared to PBS controls was observed with increasing concentrations of AuPs and was maintained in vivo at 337-863 HU. Overall, these results demonstrate that a polymersome-based system for AuNPs enhances CT image contrast, suggesting that this approach could be feasible for improving GBM detection via CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.